The Application Effect of Diltiazem Hydrochloride Combined with Sacubitril Valsartan on Chronic Heart Failure after Coronary Intervention
10.13241/j.cnki.pmb.2025.19.005
- VernacularTitle:盐酸地尔硫卓联合沙库巴曲缬沙坦对冠状动脉介入术后慢性心力衰竭的应用效果
- Author:
Xuan WANG
1
;
De-rong ZHUANG
1
;
Long TIAN
1
;
Xiao-li BIAN
1
;
Yang LI
1
Author Information
1. 扬州大学附属江都人民医院(扬州市江都区人民医院)心内科 江苏扬州 225200
- Publication Type:Journal Article
- Keywords:
Diltiazem;
Sacubitril valsartan;
Coronary intervention surgery;
Chronic heart failure;
Heart function;
Cardiovascular adverse events
- From:
Progress in Modern Biomedicine
2025;25(19):3070-3076
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the application effect of diltiazem hydrochloride combined with sacubitril valsartan on chronic heart failure after coronary intervention(PCI).Methods:A prospective study was conducted.The cases were included from May 2020 to May 2023.After the inclusion and exclusion criteria were deleted,a total of 88 patients with chronic heart failure after PCI met the research requirements.They were divided into two groups with the same number of cases,namely 44 cases in each group.The control group received oral treatment with sacubitril and valsartan,while the observation group received additional treatment with diltiazem hydrochloride on top of the control group.Compare the clinical efficacy,changes in cardiac function related indicators and exercise endurance before and after treatment between two groups,and conduct a 1-year follow-up of all patients to record the incidence of cardiovascular adverse events during the follow-up period.Finally,compare the changes in quality of life before and after treatment between the two groups of patients.Results:The total effective rate of the observation group was 93.18％,which was higher than the control group's 77.27％(P＜0.05);After treatment,the changes of cardiac function related indexes and exercise tolerance were compared.It was found that the N-terminal B-type natriuretic peptide(NT proBNP)(45.14±6.34)pg/mL,LVEDD(51.66±3.04)mm and LVESD(32.63±4.45)mm in the observation group were lower than those in the control group,while the left ventricular ejection fraction(LVEF)(55.57±4.25)％and 6MWT(514.62±34.42)m in the observation group were higher than those in the control group(P＜0.05);During the 1-year follow-up,no death occurred in the two groups.The incidence of cardiovascular adverse events in the observation group was 4.55％,much lower than 20.45％in the control group(P＜0.05);After treatment,the scores of emotion,body,others and MLHFQ in the observation group(13.53±2.21,14.25±2.63,20.35±4.52,48.13±5.25)were lower than those in the control group(P＜0.05).Conclusion:The combination of Diltiazem Hydrochloride and Sacubitril Valsartan has significant therapeutic effects on patients with chronic heart failure after PCI.It can improve patients' cardiac function and exercise endurance,reduce the incidence of cardiovascular adverse events,and improve their quality of life.
